κ-Opioid receptors are not necessary for the antidepressant treatment of neuropathic pain.

Date publication

février 2015

Journal

British journal of pharmacology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr YALCIN CHRISTMANN Ipek , Dr BARROT Michel

Tous les auteurs :
Megat S, Bohren Y, Doridot S, Gaveriaux-Ruff C, Kieffer BL, Freund-Mercier MJ, Yalcin I, Barrot M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/25297905

Résumé

Tricyclic antidepressants are used clinically as first-line treatments for neuropathic pain. Opioid receptors participate in this pain-relieving action, and preclinical studies in receptor-deficient mice have highlighted a critical role for δ-, but not μ-opioid receptors. In this study, we investigated whether κ-opioid (KOP) receptors have a role in the antiallodynic action of tricyclic antidepressants.

Mots clés

Animals, Antidepressive Agents, Tricyclic, pharmacology, Male, Mice, Inbred C57BL, Mice, Knockout, Naltrexone, analogs & derivatives, Neuralgia, drug therapy, Nortriptyline, pharmacology, Receptors, Opioid, delta, antagonists & inhibitors, Receptors, Opioid, kappa, antagonists & inhibitors, Sciatic Nerve, injuries

Référence

Br J Pharmacol. 2015 02;172(4):1034-44